mx 100

LLC1, a derivative of amiloride, exhibits cytotoxicity against breast cancer cells, particularly those resistant to other treatments. The compound demonstrates varied IC50 values across several breast cancer cell lines, including 13 mM for MCF7, 12 mM for MCF7 MX-100, 25 mM for MCF7 TS, 26 mM for MCF7 TR-1, and 19 mM for MCF7 TR-5. LLC1 holds potential for research in cancer therapy.

PL 100 could inhibit HIV-1 protease.

S-72 acts as a microtubule polymerization inhibitor, effective in cell-free assays at concentrations of 1, 3, and 10 µM. At nanomolar levels (IC50s = 15.64 and 26.32 nM, respectively), it diminishes the viability of both MCF-7 and paclitaxel-resistant MCF-7/T breast cancer cells. Moreover, at 50 nM, S-72 impedes migration, invasion, and wound healing in these cell lines. Additionally, at 100 nM, it arrests the cell cycle at the G2/M phase and induces apoptosis in MCF-7/T cells, while also inhibiting stimulator of interferon genes (STING) activation. In vivo, S-72 dosage at 15 mg/kg per day curtails tumor growth in mouse xenograft models of paclitaxel-resistant breast cancer, specifically MCF-7/T and MX-1/T.